Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. The company also provides tazobactam, piperacillin, sultamicillin, sultamicillin tosylate, tazobactam sodium, sulbactam sodium, sulbactam pivoxil, avibactam sodium, sitafloxacin, torasemide, moxifloxacin hydrochloride, paroxetine hydrochloride, and berberine hydrochloride products. In addition, it offers lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Jingdezhen, China.